T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor.
Cytomegalovirus (CMV) infection in patients receiving hematopoietic stem cell transplants (HSCT) is associated with morbidity and mortality. Adoptive T cell immunotherapy has been used to treat viral reactivation but is hardly feasible in high-risk constellations of CMV-positive HSCT patients and CMV-negative stem cell donors. We endowed human effector T cells with a chimeric immunoreceptor (cIR) directed against CMV glycoprotein B. These cIR-engineered primary T cells mediated antiviral effector functions such as cytokine production and cytolysis. This first description of cIR-redirected CMV-specific T cells opens up a new perspective for HLA-independent immunotherapy of CMV infection in high-risk patients.
Virologisches Institut, Universitätsklinikum Erlangen, Schlossgarten 4, Erlangen, Germany.
Florian
F
Full
Manfred
M
Lehner
Veronika
V
Thonn
Gabriel
G
Goetz
Brigitte
B
Scholz
Kerstin B
KB
Kaufmann
Michael
M
Mach
Hinrich
H
Abken
Wolfgang
W
Holter
Armin
A
Ensser
D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000276:immunology* / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D011971:Receptors, Immunologic / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology*
D011971:Receptors, Immunologic